| __timestamp | Lantheus Holdings, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 91733000 |
| Thursday, January 1, 2015 | 78634000 | 87644000 |
| Friday, January 1, 2016 | 75374000 | 92365000 |
| Sunday, January 1, 2017 | 92157000 | 85656000 |
| Monday, January 1, 2018 | 93326000 | 88196000 |
| Tuesday, January 1, 2019 | 103132000 | 89971000 |
| Wednesday, January 1, 2020 | 110171000 | 93413000 |
| Friday, January 1, 2021 | 218817000 | 91355000 |
| Saturday, January 1, 2022 | 233827000 | 113676000 |
| Sunday, January 1, 2023 | 267194000 | 198366000 |
| Monday, January 1, 2024 | 218935000 |
Unveiling the hidden dimensions of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Lantheus Holdings, Inc. and Taro Pharmaceutical Industries Ltd. have demonstrated contrasting strategies in optimizing these costs.
From 2014 to 2023, Lantheus Holdings saw a significant increase in SG&A expenses, peaking at approximately 267 million in 2023, a staggering 270% rise from 2014. This suggests a strategic investment in growth and expansion. In contrast, Taro Pharmaceutical maintained a more stable SG&A trajectory, with expenses increasing by only 140% over the same period, reaching around 198 million in 2023.
While Lantheus's aggressive approach may indicate a focus on scaling operations, Taro's steadier path reflects a commitment to cost efficiency. The missing data for Lantheus in 2024 leaves room for speculation on future strategies.
Selling, General, and Administrative Costs: Intra-Cellular Therapies, Inc. vs Taro Pharmaceutical Industries Ltd.
Ascendis Pharma A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Axsome Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd.
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends